US Bancorp
TARO

US Bancorp’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

US Bancorp’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-156
Closed -$6.61K – 4137
2024
Q1 		$6.61K Sell
156
-74
-32% -$3.12K ﹤0.01% 3459
2023
Q4 		$9.61K Sell
230
-1,046
-82% -$38.6K ﹤0.01% 3325
2023
Q3 		$48.1K Sell
1,276
-7,067
-85% -$265K ﹤0.01% 2460
2023
Q2 		$316K Sell
8,343
-382
-4% -$12K ﹤0.01% 1641
2023
Q1 		$212K Sell
8,725
-28
-0.3% -$817 ﹤0.01% 1837
2022
Q4 		$254K Sell
8,753
-1,052
-11% -$31.2K ﹤0.01% 1730
2022
Q3 		$295K Sell
9,805
-286
-3% -$9.86K ﹤0.01% 1650
2022
Q2 		$365K Sell
10,091
-396
-4% -$15.1K ﹤0.01% 1603
2022
Q1 		$453K Buy
10,487
+444
+4% +$20.7K ﹤0.01% 1570
2021
Q4 		$502K Sell
10,043
-653
-6% -$36.6K ﹤0.01% 1524
2021
Q3 		$681K Sell
10,696
-448
-4% -$31K ﹤0.01% 1377
2021
Q2 		$801K Sell
11,144
-303
-3% -$22.3K ﹤0.01% 1312
2021
Q1 		$844K Buy
11,447
+9
+0.1% +$683 ﹤0.01% 1223
2020
Q4 		$839K Sell
11,438
-814
-7% -$52.3K ﹤0.01% 1173
2020
Q3 		$673K Sell
12,252
-49
-0.4% -$3.05K ﹤0.01% 1171
2020
Q2 		$818K Sell
12,301
-1,035
-8% -$69.4K ﹤0.01% 1045
2020
Q1 		$817K Sell
13,336
-1,085
-8% -$80.4K ﹤0.01% 987
2019
Q4 		$1.27M Sell
14,421
-756
-5% -$63.8K ﹤0.01% 950
2019
Q3 		$1.15M Buy
15,177
+1,691
+13% +$137K ﹤0.01% 975
2019
Q2 		$1.15M Buy
13,486
+4,421
+49% +$437K ﹤0.01% 1013
2019
Q1 		$979K Buy
9,065
+8,984
+11,091% +$894K ﹤0.01% 1072
2018
Q4 		$7K Buy
81
+33
+69% +$3.18K ﹤0.01% 3137
2018
Q3 		$5K Sell
48
-66
-58% -$7.14K ﹤0.01% 3338
2018
Q2 		$13K Sell
114
-50
-30% -$5.49K ﹤0.01% 3076
2018
Q1 		$16K Sell
164
-815
-83% -$82.6K ﹤0.01% 3012
2017
Q4 		$102K Sell
979
-457
-32% -$50.2K ﹤0.01% 2247
2017
Q3 		$162K Sell
1,436
-1,547
-52% -$168K ﹤0.01% 1973
2017
Q2 		$334K Buy
2,983
+986
+49% +$111K ﹤0.01% 1577
2017
Q1 		$233K Buy
1,997
+830
+71% +$91.9K ﹤0.01% 1749
2016
Q4 		$123K Sell
1,167
-4,299
-79% -$450K ﹤0.01% 2022
2016
Q3 		$605K Sell
5,466
-193
-3% -$25.6K ﹤0.01% 1266
2016
Q2 		$824K Buy
5,659
+71
+1% +$10.1K ﹤0.01% 1111
2016
Q1 		$800K Buy
5,588
+85
+2% +$12.1K ﹤0.01% 1095
2015
Q4 		$850K Sell
5,503
-2,854
-34% -$417K ﹤0.01% 1047
2015
Q3 		$1.2M Buy
8,357
+725
+9% +$101K 0.01% 876
2015
Q2 		$1.1M Buy
7,632
+12
+0.2% +$1.71K ﹤0.01% 972
2015
Q1 		$1.07M Buy
+7,620
New +$1.17M ﹤0.01% 984

Other funds holding TARO

KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
AIIMS
Analyst IMS Investment Management Services Tel-Aviv, Israel $3.3B AUM 20.27% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
LI
LRI Investments Palm Beach Gardens, Florida $1.24B AUM 11.13% 1-Year Est. Return
GCM
Gladius Capital Management Chicago, Illinois $2.24B AUM 23.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

US Bancorp's TARO Position: Q2 2024 in Review

US Bancorp sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q2 2024, closing a stake of 156 shares — an estimated $6.61K sold.

US Bancorp first reported a position in TARO in Q1 2015 and held it in 37 quarters. The position peaked at $1.27M in Q4 2019. 16 funds tracked by Wall St. Rank hold TARO as of Q2 2024.

  • US Bancorp reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q2 2024 after selling out during the quarter.
  • US Bancorp sold 156 Taro Pharmaceutical Industries Ltd. shares in Q2 2024, an estimated $6.61K.
  • US Bancorp first reported a position in Taro Pharmaceutical Industries Ltd. in Q1 2015 and held it in 37 quarters.
  • US Bancorp's Taro Pharmaceutical Industries Ltd. position peaked at $1.27M in Q4 2019.
  • 16 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q2 2024.

Based on US Bancorp's 13F filing for Q2 2024, filed 7 Aug 2024.